Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties

Corman, Hannah N.; Ross, Jessica; Fields, Francisco R.; Shoue, Douglas A.; Lee, Shaun W.; McDowell, Mary Ann

doi:10.1128/spectrum.02658-22

Cited by 4 publications

(7 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 Additionally, the 4-amino acid AMP KDEL (consisting of lysine, aspartic acid, glutamic acid, and leucine) and the Jellein peptide, which was previously reported and produced from bee royal jelly, have demonstrated notable activity against the leishmania parasite. 40 Furthermore, skin secretions of the frog species Bombina variegata contain the bombinins H2 and H4, which exhibit robust antileishmanial activity 41 (Table 2).…”

Section: ■ Antibacterial Peptidesmentioning

confidence: 99%

Combating Antimicrobial Resistance by Employing Antimicrobial Peptides: Immunomodulators and Therapeutic Agents against Infectious Diseases

Mehraj,

Hamid,

Gani

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

The rising prevalence of multiple-drug-resistant pathogens poses a formidable challenge to conventional antimicrobial treatments. The inability of potent antibiotics to combat these “superbugs” underscores the pressing need for alternative therapeutic agents. Antimicrobial peptides (AMPs) represent an alternative class of antibiotics. AMPs are essential immunomodulatory molecules that are found in various organisms. They play a pivotal role in managing microbial ecosystems and bolstering innate immunity by targeting and eliminating invading microorganisms. AMPs also have applications in the agriculture sector by combating animal as well as plant pathogens. AMPs can be exploited for the targeted therapy of various diseases and can also be used in drug-delivery systems. They can be used in synergy with current treatments like antibiotics and can potentially lead to a lower required dosage. AMPs also have huge potential in wound healing and regenerative medicine. Developing AMP-based strategies with improved safety, specificity, and efficacy is crucial in the battle against alarming global microbial resistance. This review will explore AMPs’ increasing applicability, their mode of antimicrobial activity, and various delivery systems enhancing their stability and efficacy.

show abstract

Section: ■ Antibacterial Peptidesmentioning

confidence: 99%

Combating Antimicrobial Resistance by Employing Antimicrobial Peptides: Immunomodulators and Therapeutic Agents against Infectious Diseases

Mehraj,

Hamid,

Gani

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…This preference is presumably because mammalian cells contain zwitterionic phospholipids in their membranes, while conversely, the membranes of Leishmania parasites have an anionic nature. However, even though AMPs and CPPs have shown selective binding to the parasite membrane, some of these compounds exert less activity against amastigote forms [ 46 , 47 , 48 , 49 ]. This is likely due to the different surface charges in different Leishmania life stages.…”

Section: Amps and Cpps As Alternative Therapies To Conventional Drugs...mentioning

confidence: 99%

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease

Robledo,

Pérez-Silanes,

Fernández-Rubio

et al. 2023

Pathogens

View full text Add to dashboard Cite

In 2020, the WHO established the road map for neglected tropical diseases 2021–2030, which aims to control and eradicate 20 diseases, including leishmaniosis and Chagas disease. In addition, since 2015, the WHO has been developing a Global Action Plan on Antimicrobial Resistance. In this context, the achievement of innovative strategies as an alternative to replace conventional therapies is a first-order socio-sanitary priority, especially regarding endemic zoonoses in poor regions, such as those caused by Trypanosoma cruzi and Leishmania spp. infections. In this scenario, it is worth highlighting a group of natural peptide molecules (AMPs and CPPs) that are promising strategies for improving therapeutic efficacy against these neglected zoonoses, as they avoid the development of toxicity and resistance of conventional treatments. This review presents the novelties of these peptide molecules and their ability to cross a whole system of cell membranes as well as stimulate host immune defenses or even serve as vectors of molecules. The efforts of the biotechnological sector will make it possible to overcome the limitations of antimicrobial peptides through encapsulation and functionalization methods to obtain approval for these treatments to be used in clinical programs for the eradication of leishmaniosis and Chagas disease.

show abstract

“…This preference is presumably because mammalian cells contain zwitterionic phospholipids in their membrane while, conversely, the membranes of Leishmania parasites have an anionic nature. However, even though AMPs and CPPs have shown selective binding to the parasite membrane, some of these compounds exert less activity against amastigote forms [44][45][46][47]. This is likely due to the different surface charge between Leishmania life stages.…”

Section: Amps and Cpps As Alternative Therapies Vs Conventional Drugs...mentioning

confidence: 99%

“…The promastigote form is strongly negatively charged, mainly due to the content of surface lipophosphoglycans (LPG, which covers more than 60% of the surface); instead, LPG is present at very low or non-detectable levels in the amastigote form [48]. The external covering of the amastigotes is made up primarily of glycoinositolphospholipids (GIPLs) [49], and the affinity of the peptides for the plasma membrane of amastigotes could be decreased [45]. Thus, it should be noted that these studies show promastigote sensitivity to AMP more than amastigotes [50].…”

Section: Amps and Cpps As Alternative Therapies Vs Conventional Drugs...mentioning

confidence: 99%

See 1 more Smart Citation

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas

Robledo,

Pérez-Silanes,

Fernández-Rubio

et al. 2023

Preprint

View full text Add to dashboard Cite

In 2020, the WHO established a road map for neglected tropical diseases 2021−2030 that aims to control and eradicate 20 diseases, including Leishmaniosis and Chagas disease. In addition, since 2015, the WHO has been developing a Global Action Plan on Antimicrobial Resistance. In this context, the achievement of innovative strategies as an alternative to replace conventional therapies is a first-order socio-sanitary priority, especially regarding endemic zoonoses in poor regions such as those caused by Trypanosoma cruzi and Leishmania spp infections. In this scenario, it is worth highlighting a group of natural peptide molecules (AMPs and CPPs) that are promising strategies for improving therapeutic efficacy against these neglected zoonoses, avoiding the development of toxicity and resistance of conventional treatments. This review presents the novelties of these peptide molecules and their ability to cross a whole system of cell membranes, as well as to stimulate the host immune defenses or even serve as a vector of molecules. The efforts of the biotechnological sector will make it possible to overcome the limitations of antimicrobial peptides through encapsulation and functionalization methods to obtain approval for these treatments to be used in clinical programs for the eradication of Leishmaniosis and Chagas disease.

show abstract

Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties

Abstract: Leishmaniasis is a neglected tropical disease caused by protozoan parasites of the genus Leishmania . There are three primary clinical forms, cutaneous, mucocutaneous, and visceral, with visceral leishmaniasis being fatal if left untreated.

Cited by 4 publications

References 73 publications

Combating Antimicrobial Resistance by Employing Antimicrobial Peptides: Immunomodulators and Therapeutic Agents against Infectious Diseases

Combating Antimicrobial Resistance by Employing Antimicrobial Peptides: Immunomodulators and Therapeutic Agents against Infectious Diseases

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease

Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas

Contact Info

Product

Resources

About